Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2021

12/01/2021 | 01:30am EST

Biovica International AB (publ) reported earnings results for the second quarter and six months ended October 31, 2021. For the second quarter, the company reported sales was SEK 0.917 million compared to SEK 0.924 million a year ago. Revenue was SEK 0.991 million compared to SEK 3.57 million a year ago. Net loss was SEK 14.39 million compared to SEK 8.21 million a year ago. Basic loss per share from continuing operations was SEK 0.51 compared to SEK 0.29 a year ago. Diluted loss per share from continuing operations was SEK 0.51 compared to SEK 0.29 a year ago. For the six months, sales was SEK 2.18 million compared to SEK 2.92 million a year ago. Revenue was SEK 2.32 million compared to SEK 5.65 million a year ago. Net loss was SEK 26.61 million compared to SEK 16.58 million a year ago. Basic loss per share from continuing operations was SEK 0.93 compared to SEK 0.59 a year ago. Diluted loss per share from continuing operations was SEK 0.93 compared to SEK 0.59 a year ago.


ę S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
2021Biovica International
AQ
2021Q2 Interim report - Promising results published at ESMO
AQ
2021Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Biovica International AB Provides Earnings Guidance for the Full Year 2021
CI
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
2021Biovica International
AQ
2021Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
2021Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
2021Biovica International
AQ
More news
Financials
Sales 2022 39,0 M 4,24 M 4,24 M
Net income 2022 -28,0 M -3,04 M -3,04 M
Net cash 2022 110 M 12,0 M 12,0 M
P/E ratio 2022 -37,9x
Yield 2022 -
Capitalization 1 068 M 116 M 116 M
EV / Sales 2022 24,6x
EV / Sales 2023 5,13x
Nbr of Employees 24
Free-Float -
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 37,50 SEK
Average target price 103,00 SEK
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-9.42%116
EXACT SCIENCES CORPORATION-4.88%12 757
GUARDANT HEALTH, INC.-29.91%7 126
BGI GENOMICS CO., LTD.1.37%5 755
SEEGENE, INC.-1.31%2 606
INVITAE CORPORATION-29.21%2 447